EP1763335A1 - Mlv cosmetic product - Google Patents
Mlv cosmetic productInfo
- Publication number
- EP1763335A1 EP1763335A1 EP05759725A EP05759725A EP1763335A1 EP 1763335 A1 EP1763335 A1 EP 1763335A1 EP 05759725 A EP05759725 A EP 05759725A EP 05759725 A EP05759725 A EP 05759725A EP 1763335 A1 EP1763335 A1 EP 1763335A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- weight
- cosmetic
- formulation according
- dermatological formulation
- fatty acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Definitions
- the invention relates to lecithin and essential fatty acids containing cosmetic and / or dermatological formulations which ensure maximum hydration of the skin with a simultaneous acceleration of metabolic processes, so that the healing process of damaged skin is supported.
- the formulations according to the invention give a remarkably pleasant feeling on the skin.
- a cosmetic and / or dermatological formulation achieves the stated object if this formulation contains lecithin, as lipid phase a native oil with a defined, preferably high, content of fatty acids, in particular essential fatty acids, e.g.
- Sunflower oil and glycerol (and / or ethylene glycol, 1, 3-propanediol and / or tert-butyl alcohol), propylene glycol (and / or polyethylene glycol), benzyl alcohol (and / or benzylacetone and / or benzaldehyde), phenylethyl alcohol (and / or 2-phenylacetate ), Benzyl alcohol (and / or phenylethyl alcohol) and purified water.
- Lecithin belongs to the group of phosphoglycerides, which are also called phosphatides or phospholipids. These compounds are fat-like triglycerides with two long-chain fatty acids and one Phosphoric acid residue, to which an ammonium radical is attached, as shown below:
- Lecithin is not a pure substance but a mixture of different fatty acid esters depending on their origin. Particularly preferred is the use of lecithin from chicken eggs and / or soybeans. Another source is e.g. Rape.
- the lecithin from soya is obtained by extraction of the soya with ethanol and the lecithin purified by chromatography is then hydrogenated.
- the phosphatidylcholine (lecithin) thus obtained contains 80% to 90% stearic acid, preferably about 85% stearic acid and 10% by weight to 20% by weight palmitic acid, preferably about 15% palmitic acid, as fatty acid residues.
- a particularly suitable lecithin is the Phospholipon available from PHOSPHOLIPID GmbH, Cologne, Germany ® 80 H and the Phospholipon ® 90 H.
- Lecithin is widely used in cosmetic formulations. As a component of ointments and creams it promotes the permeation of active ingredients into the skin and significantly improves the water retention capacity of the stratum corneum in gel preparations. Due to the increase in moisture absorption of the skin, the roughness of the skin is lowered. As an emulsifier, lecithin has a very low irritation potential (no washout effect). With lecithin W / O emulsions with high water content can be produced. Lecithin is a natural antioxidant and is used as an emulsifier in bath oils. Hydrogenated lecithin is suitable as a gelling and thickening agent in cosmetic preparations.
- Another essential component of the formulations according to the invention are essential fatty acids which are preferably added to the formulation in the form of suitable oils.
- suitable oils include sunflower oil, olive oil, corn oil, linseed oil, cod liver oil and fish oil.
- These oils of native origin are added to the formulations of the present invention in an amount of 3.0-20.0 wt%, preferably 6.0-16.0 wt%, more preferably 7-14 wt% preferably 8.0-12.0% by weight, more preferably still 9-11% by weight, and especially preferably 10.0% by weight.
- oils of natural origin are selected according to their content and composition of fatty acids, including essential fatty acids, dermatologically and their technological suitability.
- the refined sunflower oil in pharm. EUR. Quality is preferred for the formulations of the invention.
- This refined sunflower oil (Helianthi annui oleum raffinatum) is obtained from the seed of Helianthus annuus C., has a specific gravity of 0.921 and a refractive index of 1.474, an acid value of at most 0.5 (determined with 10 g of substance), a peroxide value !
- fatty acid composition palmitic acid 4% by weight - 9% by weight, stearic acid 1% by weight - 7% by weight, oleic acid 14% by weight - 40% by weight and linoleic acid 48% by weight. -% - 74 wt .-%.
- sunflower oil (Helianthus annuus L) consists of 39 wt .-% oleic acid, 34 wt .-% ⁇ -linoleic acid, 13 wt .-% ß-linoleic acid, about 4 wt .-% glycerol, about 9 wt .-% saturated fatty acids (palmitic, stearic, arachic and linoceric), carotenoids and lecithin.
- the fatty acid fraction of the sunflower oils used preferably contains 15-35% by weight of oleic acid, 50-72% by weight of linoleic acid.
- Oleic acid is also known as Acidum oleinicum, cis-9-octadecenoic acid, oleic acid or oleic acid.
- EFAs Essential fatty acids
- Essential fatty acids always exist in the cis and not in the trans configuration and are characterized by two or more unsaturated carbon atoms, ie by at least one double bond. Characteristic is the position at which the first double bond in the fatty acid chain, as seen from the end of the methyl end (omega end), is positioned.
- omega-6 derived from cis-linolenic acid
- omega-3 derived from alpha-linolenic acid.
- the most important groups of omega fatty acids are omega-3, -6 and -9 fatty acids.
- the omega-3 fatty acids include ⁇ -linolenic acid, eicosapentaenoic acid and docohexaenoic acid.
- Omega-6 fatty acids include ⁇ -linolenic acid, linoleic acid, arachidonic acid, delta-is-cis-cis-docosadienoic acid (22: 2), delta-11-cis, 14-cis-eicosa- / icosadienoic acid (20: 2) and delta-7-cis, 10-cis-hexadecadienoic acid (16: 2).
- the omega-9 fatty acids include oleic acid (delta-9-octadecenoic acid, 18: 1), gondoic acid (delta-11-cis-eicosenic / icosenoic acid, 20: 1), erucic acid (delta-13-cis-docosenoic acid, 22 : 1) as well as nervonic acid (delta-15-cis-tetracenoic acid, 24: 1).
- linoleic acid The highest content of linoleic acid is found in vegetable oils such as safflower or safflower oil, sunflower hemp and soybean oil, and vegetable margarine.
- the threefold unsaturated alpha-linolenic acid (9,12,15-octadecatrienoic acid) is mainly present in linseed oil (55%), walnut oil (14%), rapeseed oil (11%) and hemp oil (7%).
- Table 1 shows important omega-3 and 6-fatty acids, their chain length and position as well as their occurrence.
- unsaturated fatty acids are preferably selected from the group comprising oleic acid, eicosapentaenoic acid, timnodonic acid, docosahexaenoic acid, arachidonic acid, linoleic acid, ⁇ -linolenic acid, ⁇ -1-nolinic acid and mixtures of the abovementioned fatty acids. These mixtures comprise in particular mixtures of the pure unsaturated compounds.
- oils are preferably used as component b which contain at least 20%, preferably at least 25%, more preferably at least 30% and especially preferably at least 35% of omega fatty acids.
- omega fatty acids especially the omega-9 fatty acids are preferred and among the omega-9 fatty acids in particular the oleic acid. Furthermore, the omega-6 fatty acids are particularly suitable for the production of the formulation according to the invention and the linoleic acid among the omega-6 fatty acids.
- the oils used as component b according to the invention preferably contain more than 78% by weight of oleic and linoleic acid, more preferably more than 86% by weight and more preferably more than 93% by weight of oleic and linoleic acid.
- the oils used as component b preferably contain more than 13% by weight of oleic acid, more preferably more than 24% by weight of oleic acid and more preferably more than 34% by weight of oleic acid.
- oils as component b contain more than 38% by weight of linoleic acid ( ⁇ -linoleic acid + ⁇ -linoleic acid), preferably more than 47% by weight of linoleic acid, more preferably more than 57% by weight of linoleic acid and particularly preferably more than 67% by weight of linoleic acid.
- Another particularly suitable oil is a sunflower oil (Helianthus annuus L.) containing 39% by weight of oleic acid, 34% by weight of ⁇ -linoleic acid and 13% by weight of ⁇ -linoleic acid,
- oils are linseed oil, hemp oil, corn oil, walnut oil, rapeseed oil, soybean oil, sunflower oil, poppy seed oil, safflower oil, wheat germ oil, thistle oil, grape seed oil, evening primrose oil, borage oil, black cumin oil, algae oil, fish oil, cod liver oil and / or mixtures of the aforementioned oils , Particularly suitable is sunflower oil. It is also possible to add one or more essential fatty acids to the oils to provide the necessary amount of essential fatty acids.
- Fish oil and cod liver oil mainly contain eicosapentaenoic acid (EPA C20: 5) and docosahexaenoic acid (DHA C22: 6) in addition to low alpha-linolenic acid (ALA C18: 3).
- Omega-3 fatty acids are found not only in fish oil but also in vegetable oils. Table 2 below shows a list of fatty acid components in various oils.
- Tables 3, 4 and 5 show a list of monoolefinic, polyunsaturated and acetylenic fatty acids which are preferably used in the present invention.
- Non-essential fatty acids or trans-fatty acids may also be added to the formulation according to the invention together with the essential fatty acids, the abovementioned weight percentage being at least 30% by weight, preferably 40% by weight and in particular at least 50% by weight of essential Fatty acids should not fall below.
- the maximum amount by weight of essential fatty acids should not exceed 25 g per 100 g formulation
- the cosmetic and / or dermatological formulations according to the invention contain glycerol as an 85% solution in water, propylene glycol or polyethylene glycol as bodying agent, benzyl alcohol, benzylacetone and / or benzaldehyde and also phenylethyl alcohol and / or 2-phenylacetate.
- the glycerol used can have a water content of up to 20%.
- ethylene glycol, 1, 3-propanediol, tert-butyl alcohol! and / or alcohols having boiling points above 125 ° C preferably above 15O 0 C and preferably diols or triols are used.
- Benzyl alcohol, benzylacetone and / or benzaldehyde are added as permeability enhancers to accelerate metabolic processes in the skin as well as stabilizing agents for the formulation.
- Phenylethyl alcohol and 2-phenylacetate also serve as permeability enhancers for accelerating metabolic processes in the skin and also stabilize the formulation.
- benzylic alcohol and phenylethyl alcohol also lead to an unexpected synergistic effect between the components of the cosmetic and / or dermatological formulation according to the invention, which As a result, with very good moisturizing of the skin, metabolic processes in the skin are stimulated and accelerated and, in addition, a support of the lipid barrier takes place. As a result, the formulations according to the invention are suitable both for the treatment of damaged skin and for the smoothing of wrinkles with prolonged use.
- formulations which are not only suitable for dermatological use, for example in acne, atopic dermatitis and / or dermatitis, but at the same time also achieve a cosmetic effect, for example the smoothing of wrinkles by the support of the structure as well as the regeneration of the lipid barrier and / or the stimulation as well as acceleration of metabolic processes in the skin.
- a cosmetic effect for example the smoothing of wrinkles by the support of the structure as well as the regeneration of the lipid barrier and / or the stimulation as well as acceleration of metabolic processes in the skin.
- Particularly advantageous is the addition of benzyl alcohol and / or phenylethyl alcohol, which also contribute to a marked increase in viscosity in addition to a pronounced synergistic effect.
- This significant spontaneous increase in viscosity achieved in particular by benzyl alcohol is essential for the matrix or gel skeleton formation and thus for the dermatological / cosmetic function of the formulations according to the invention.
- propylene glycol which is preferably present in weight percentages of at least 8 wt%, more preferably 9 wt%, 10 wt%, 11 wt%, 12 wt%, 13 wt%. -%, And particularly preferably 14 wt .-% is used.
- the function of propylene glycol in the formation of the special framework structure of the formulations according to the invention has not yet been clarified, but an effect on the consistency of the formulation is clearly detectable.
- the cosmetic and / or dermatological formulations according to the invention contain lecithin in an amount of 0.5-20.0% by weight, preferably 2.0-10.0% by weight, more preferably 3.0-5.0% by weight. -%, and more preferably 4.0 wt .-%.
- Glycerol is added as an 85% solution in water in an amount of 0.5-30.0% by weight, preferably 3.0-10.0% by weight, more preferably 5.0-7.0% by weight. -%, even more preferably 4.5 to 6.0 wt .-% and particularly preferably 5.0 wt .-% used.
- the amount of propylene glycol and / or polyethylene glycol used is 0.5-50.0 wt%, preferably 6-35 wt%, 7-30 wt%, 7.5-28 wt%, 8 - 26 wt .-%, 8.5 - 25 wt .-%, 9 - 24 wt .-%, 9.5 - 23 wt .-%, more preferably 10.0 - 22.0 wt .-%, further preferably 11-21% by weight, 12-20% by weight, 13-19% by weight, even more preferably 14.0-18.0% by weight, furthermore preferably 15-17% by weight. % and most preferably 16.0 wt .-%.
- the aforementioned weight percentages are only for propylene glycol, i.
- Polyethylene glycol is not present.
- Benzyl alcohol, benzylacetone and / or benzaldehyde are used in an amount of 0.1-15.0% by weight, preferably 1.0-10.0% by weight, more preferably 2.0-4.0% by weight. and particularly preferably used of 3.0 wt .-%.
- the cosmetic and / or dermatological formulations according to the invention comprise phenylethyl alcohol and / or 2-phenylacetate in an amount of 0.1-15.0% by weight, preferably 0.2-5.0% by weight, furthermore preferably 0.3 - 1, 5 wt .-% and particularly preferably 0.5 wt .-%.
- Purified water is added to the above ingredients in an amount to supplement the formulation to 100% by weight (ad 100% by weight).
- lecithin preferably a formulation of the following ingredients: lecithin, native oil with a defined content of essential fatty acids, such as e.g. Sunflower oil and glycerin, propylene glycol, benzyl alcohol, phenylethyl alcohol and purified water.
- essential fatty acids such as e.g. Sunflower oil and glycerin
- propylene glycol propylene glycol
- benzyl alcohol benzyl alcohol
- phenylethyl alcohol preferably purified water.
- compositions according to the invention may also be supplemented with customary odorants or perfumes, dyes, preservatives, viscosity-increasing substances and / or UV filters.
- customary odorants or perfumes are used in particular to increase the color, light and / or perfume stability of Formulations or shelf life or consistency.
- Such additives are present in total in not more than 10 wt .-%, preferably 8 wt .-%, more preferably 6 wt .-% and particularly preferably 4 wt .-% in the formulation.
- the cosmetic and / or dermatological formulations according to the invention can advantageously be used for the treatment of all forms from impure to damaged skin. From blemished to damaged skin, for example, all forms of acne, atopic dermatitis or atypical dermatitis are to be understood.
- Cosmetic and / or dermatological formulations are, in particular, skin creams, skin lotions, milks, ointments, oils and balms and all other formulations suitable for topical application.
- Example 1 Example 4: Example 7: Example 10:
- Detection of the viscosity increase A suspension of 100 g of lecithin (phosphatidylcholine 8OH, Fa. Lipoid) and 900 g of water is mixed with 20 g of benzyl alcohol at 30 - 4O 0 C.
- the viscosity before the addition of the benzyl alcohol was about 2180 mPas (Haake RV / 7 (Brookfield) immersion R3, 30 up / m, 38 ° C) after the addition of benzyl alcohol but about 54790 mPas (immersion R5, 4 up / m , 34 ° C).
- the viscosity increase is permanent.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to cosmetic and/or dermatological formulations which contain lecithin and essential fatty acids while ensuring that the skin is provided with a maximum of moisture and metabolic processes are accelerated so as to support the healing process of damaged skin.
Description
MLV-Kosmetikum MLV cosmetic
Beschreibungdescription
Die Erfindung betrifft Lecithin und essentielle Fettsäuren enthaltende kosmetische und/oder dermatologische Formulierungen, welche eine maximale Feuchtigkeitsversorgung der Haut bei einer gleichzeitigen Beschleunigung der Stoffwechselvorgänge sicherstellen, so dass der Heilungsprozess von geschädigter Haut unterstützt wird. Außerdem vermitteln die erfindungsgemäßen Formulierungen ein bemerkenswert angenehmes Hautgefühl.The invention relates to lecithin and essential fatty acids containing cosmetic and / or dermatological formulations which ensure maximum hydration of the skin with a simultaneous acceleration of metabolic processes, so that the healing process of damaged skin is supported. In addition, the formulations according to the invention give a remarkably pleasant feeling on the skin.
Aufgabe der vorliegenden Erfindung ist die Bereitstellung von kosmetischen und/oder dermatologischen Formulierungen, welche eine maximale Feuchtigkeitsversorgung der Haut garantieren und durch Beschleunigung der Stoffwechselvorgänge den Heilungsprozess von geschädigter Haut beschleunigen.It is an object of the present invention to provide cosmetic and / or dermatological formulations which guarantee maximum moisturization of the skin and speed up the healing process of damaged skin by accelerating the metabolic processes.
Diese Aufgabe wird durch die technische Lehre des unabhängigen Anspruchs 1 gelöst. Weitere vorteilhafte Ausgestaltungen, Aspekte und Details der Erfindung ergeben sich aus den abhängigen Ansprüchen, der Beschreibung und den Beispielen.This object is achieved by the technical teaching of independent claim 1. Further advantageous embodiments, aspects and details of the invention will become apparent from the dependent claims, the description and the examples.
Überraschenderweise wurde gefunden, dass eine kosmetische und/oder dermatologische Formulierung die gestellte Aufgabe löst, wenn diese Formulierung Lecithin, als Lipidphase ein natives Öl mit einem definierten bevorzugt hohen Gehalt an Fettsäuren insbesondere essentiellen Fettsäuren wie z.B. Sonnenblumenöl sowie Glycerin (und/oder Ethylenglykol, 1 ,3-Propandiol und/oder tert-Butylalkohol), Propylenglykol (und/oder Polyethylenglykol), Benzylalkohol (und/oder Benzylaceton und/oder Benzaldehyd), Phenylethylalkohol (und/oder 2-Phenylacetat), Benzylalkohol (und/oder Phenylethylalkohol) und gereinigtes Wasser enthält.Surprisingly, it has been found that a cosmetic and / or dermatological formulation achieves the stated object if this formulation contains lecithin, as lipid phase a native oil with a defined, preferably high, content of fatty acids, in particular essential fatty acids, e.g. Sunflower oil and glycerol (and / or ethylene glycol, 1, 3-propanediol and / or tert-butyl alcohol), propylene glycol (and / or polyethylene glycol), benzyl alcohol (and / or benzylacetone and / or benzaldehyde), phenylethyl alcohol (and / or 2-phenylacetate ), Benzyl alcohol (and / or phenylethyl alcohol) and purified water.
Lecithin gehört zur Gruppe der Phosphoglyceride, welche auch als Phosphatide oder Phospholipide bezeichnet werden. Es handelt sich bei diesen Verbindungen um fettähnliche Triglyceride mit zwei langkettigen Fettsäuren und einem
Phosphorsäurerest, woran ein Ammoniumrest gebunden ist, wie im folgenden gezeigt:Lecithin belongs to the group of phosphoglycerides, which are also called phosphatides or phospholipids. These compounds are fat-like triglycerides with two long-chain fatty acids and one Phosphoric acid residue, to which an ammonium radical is attached, as shown below:
O-Phosphatidyl-cholin (Lecithin) O-phosphatidyl-choline (lecithin)
Lecithin ist keine Reinsubstanz, sondern ein Gemisch mit je nach Herkunft unterschiedlichen Fettsäureestern. Insbesondere bevorzugt ist die Verwendung von Lecithin aus Hühnerei und/oder Soja. Eine weitere Quelle ist z.B. Raps.Lecithin is not a pure substance but a mixture of different fatty acid esters depending on their origin. Particularly preferred is the use of lecithin from chicken eggs and / or soybeans. Another source is e.g. Rape.
Das Lecithin aus Soya wird durch Extraktion des Soya mit Ethanol gewonnen und das durch Chromatographie gereinigte Lecithin wird anschließend hydriert. Das so erhaltene Phosphatidylcholin (Lecithin) enthält als Fettsäurereste 80% - 90% Stearinsäure, bevorzugt ca. 85% Stearinsäure und 10 Gew.-% - 20 Gew.-% Palmitinsäure, bevorzugt ca. 15% Palmitinsäure. Ein insbesondere geeignetes Lecithin ist das von PHOSPHOLIPID GmbH, Köln, Deutschland erhältliche Phospholipon® 80 H als auch das Phospholipon® 90 H.The lecithin from soya is obtained by extraction of the soya with ethanol and the lecithin purified by chromatography is then hydrogenated. The phosphatidylcholine (lecithin) thus obtained contains 80% to 90% stearic acid, preferably about 85% stearic acid and 10% by weight to 20% by weight palmitic acid, preferably about 15% palmitic acid, as fatty acid residues. A particularly suitable lecithin is the Phospholipon available from PHOSPHOLIPID GmbH, Cologne, Germany ® 80 H and the Phospholipon ® 90 H.
Lecithin wird vielfältig in kosmetischen Formulierungen eingesetzt. Es fördert als Bestandteil von Salben und Cremes die Permeation von Wirkstoffen in die Haut und verbessert in Gelzubereitungen deutlich das Wasserhaltevermögen des Stratum comeums. Aufgrund der Erhöhung der Feuchtigkeitsaufnahme der Haut, wird die Rauhigkeit der Haut gesenkt. Als Emulgator weist Lecithin ein sehr geringes Irritationspotenzial auf (kein washout-Effekt). Mit Lecithin sind W/O- Emulsionen mit hohem Wassergehalt herstellbar. Lecithin ist ein natürliches Antioxidans und wird als Emulgator in Badeölen eingesetzt. Hydriertes Lecithin eignet sich als Gelatisierungs- und Verdickungsmittel in kosmetischen Zubereitungen.Lecithin is widely used in cosmetic formulations. As a component of ointments and creams it promotes the permeation of active ingredients into the skin and significantly improves the water retention capacity of the stratum corneum in gel preparations. Due to the increase in moisture absorption of the skin, the roughness of the skin is lowered. As an emulsifier, lecithin has a very low irritation potential (no washout effect). With lecithin W / O emulsions with high water content can be produced. Lecithin is a natural antioxidant and is used as an emulsifier in bath oils. Hydrogenated lecithin is suitable as a gelling and thickening agent in cosmetic preparations.
Ein weiterer wesentlicher Bestandteil der erfindungsgemäßen Formulierungen sind essentielle Fettsäuren, welche bevorzugt in Form geeigneter Öle der Formulierung beigesetzt werden. Derartige geeignete Öle sind beispielsweise Sonnenblumenöl, Olivenöl, Maisöl, Leinöl, Lebertran und Fischöl.
Diese Öle bevorzugt nativen Ursprungs werden den erfindungsgemäßen Formulierungen in einer Menge von 3,0 - 20,0 Gew.-%, bevorzugt 6,0 - 16,0 Gew.-%, ferner bevorzugt 7 - 14 Gew.-%, noch weiter bevorzugt 8,0 - 12,0 Gew.- %, ferner noch weiter bevorzugt 9 - 11 Gew.-% und insbesondere bevorzugt 10,0 Gew.-% zugesetzt.Another essential component of the formulations according to the invention are essential fatty acids which are preferably added to the formulation in the form of suitable oils. Such suitable oils include sunflower oil, olive oil, corn oil, linseed oil, cod liver oil and fish oil. These oils of native origin are added to the formulations of the present invention in an amount of 3.0-20.0 wt%, preferably 6.0-16.0 wt%, more preferably 7-14 wt% preferably 8.0-12.0% by weight, more preferably still 9-11% by weight, and especially preferably 10.0% by weight.
Diese Öle nativen Ursprungs werden nach ihrem Gehalt sowie der Zusammensetzung an Fettsäuren, inklusive essentieller Fettsäuren, in dermatologischer Hinsicht und ihrer technologischen Eignung ausgewählt. In der einschlägigen Fachliteratur sind die einzelnen dermatologisch wirksamen Bestandteile sowie deren Zusammensetzung hinreichend beschrieben. Das raffinierte Sonnenblumenöl in pharm. EUR. Qualität ist für die erfindungsgemäßen Formulierungen bevorzugt. Dieses raffinierte Sonnenblumenöl (Helianthi annui oleum raffinatum) wird aus dem Samen von Helianthus annuus C. gewonnen, besitzt eine relative Dichte von 0,921 und einen Brechungsindex von 1 ,474, eine Säurezahl von höchstens 0,5 (mit 10g Substanz bestimmt), eine Peroxidzah! von höchstens 10 sowie folgende Fettsäurenzusammensetzung: Palmitinsäure 4 Gew.-% - 9 Gew.-%, Stearinsäure 1 Gew.-% - 7 Gew.-%, Ölsäure 14 Gew.-% - 40 Gew.-% und Linolsäure 48 Gew.-% - 74 Gew.-%. Ein weiteres insbesondere geeignetes Sonnenblumenöl (Helianthus annuus L) besteht aus 39 Gew.-% Ölsäure, 34 Gew.-% α-Linolsäure, 13 Gew.-% ß-Linolsäure, ca. 4 Gew.-% Glycerol, ca. 9 Gew.-% gesättigte Fettsäuren (Palmitin-, Stearin-, Arachin- und Linocerinsäure), Carotinoide sowie Lecithin. Die Fettsäurefraktion der verwendeten Sonnenblumenöle enthält vorzugsweise 15 - 35 Gew.-% Ölsäure, 50 - 72 Gew.-% Linolsäure. Ölsäure wird unter anderem auch als Acidum oleinicum, cis-9-Octadecensäure, Elainsäure oder Oleinsäure bezeichnet.These oils of natural origin are selected according to their content and composition of fatty acids, including essential fatty acids, dermatologically and their technological suitability. In the relevant literature, the individual dermatologically active ingredients and their composition are sufficiently described. The refined sunflower oil in pharm. EUR. Quality is preferred for the formulations of the invention. This refined sunflower oil (Helianthi annui oleum raffinatum) is obtained from the seed of Helianthus annuus C., has a specific gravity of 0.921 and a refractive index of 1.474, an acid value of at most 0.5 (determined with 10 g of substance), a peroxide value ! of at most 10 and the following fatty acid composition: palmitic acid 4% by weight - 9% by weight, stearic acid 1% by weight - 7% by weight, oleic acid 14% by weight - 40% by weight and linoleic acid 48% by weight. -% - 74 wt .-%. Another particularly suitable sunflower oil (Helianthus annuus L) consists of 39 wt .-% oleic acid, 34 wt .-% α-linoleic acid, 13 wt .-% ß-linoleic acid, about 4 wt .-% glycerol, about 9 wt .-% saturated fatty acids (palmitic, stearic, arachic and linoceric), carotenoids and lecithin. The fatty acid fraction of the sunflower oils used preferably contains 15-35% by weight of oleic acid, 50-72% by weight of linoleic acid. Oleic acid is also known as Acidum oleinicum, cis-9-octadecenoic acid, oleic acid or oleic acid.
Essentielle Fettsäuren (EFA: essential fatty acids) sind Fettsäuren, welche vom menschlichen Körper nicht selbst hergestellt werden können und daher über die Nahrung aufgenommen werden müssen.Essential fatty acids (EFAs) are fatty acids that can not be produced by the human body itself and therefore need to be absorbed through the diet.
Essentielle Fettsäuren liegen immer in der eis- und nicht der trans-Konfiguration vor und zeichnen sich durch zwei oder mehrere ungesättigte Kohlenstoffatome, d. h. durch mindestens eine Doppelbindung aus. Charakteristisch ist die Stelle, an der die erste Doppelbindung in der Fettsäurekette, vom Methylende (Omega- Ende) her gesehen, positioniert ist. Es gibt zwei Arten von essentiellen Fettsäuren, die Omega-6, hergeleitet aus der cis-Linolensäure und die Omega-3, hergeleitet von der alpha-Linolensäure. Die wichtigsten Gruppen von Omega- Fettsäuren sind die Omega-3-, -6- und -9-Fettsäuren.
Zu den Omega-3-Fettsäuren gehören α-Linolensäure, Eicosapentaensäure und Docohexaensäure.Essential fatty acids always exist in the cis and not in the trans configuration and are characterized by two or more unsaturated carbon atoms, ie by at least one double bond. Characteristic is the position at which the first double bond in the fatty acid chain, as seen from the end of the methyl end (omega end), is positioned. There are two types of essential fatty acids, omega-6, derived from cis-linolenic acid and omega-3, derived from alpha-linolenic acid. The most important groups of omega fatty acids are omega-3, -6 and -9 fatty acids. The omega-3 fatty acids include α-linolenic acid, eicosapentaenoic acid and docohexaenoic acid.
Zu den Omega-6-Fettsäuren gehören γ-Linolensäure, Linolsäure, Arachidonsäure, Delta-IS-cisJΘ-cis-Docosadiensäure (22:2), Delta-11-cis,14-cis-Eicosa- /Icosadiensäure (20:2) und Delta-7-cis,10-cis-Hexadecadiensäure (16:2).Omega-6 fatty acids include γ-linolenic acid, linoleic acid, arachidonic acid, delta-is-cis-cis-docosadienoic acid (22: 2), delta-11-cis, 14-cis-eicosa- / icosadienoic acid (20: 2) and delta-7-cis, 10-cis-hexadecadienoic acid (16: 2).
Zu den Omega-9-Fettsäuren gehören Ölsäure (Delta-9-Octadecensäure; 18:1 ), Gondosäure (Delta-11-cis-Eicosen-/lcosensäure; 20:1 ), Erucasäure (Delta-13-cis- Docosensäure; 22:1 ) sowie Nervonsäure (Delta-15-cis-Tetracosensäure; 24:1 ).The omega-9 fatty acids include oleic acid (delta-9-octadecenoic acid, 18: 1), gondoic acid (delta-11-cis-eicosenic / icosenoic acid, 20: 1), erucic acid (delta-13-cis-docosenoic acid, 22 : 1) as well as nervonic acid (delta-15-cis-tetracenoic acid, 24: 1).
Der höchste Gehalt an Linolsäure findet sich in Pflanzenölen wie beispielsweise Saflor- oder Distelöl, Sonnenblumen- Hanf- und Sojaöl und in Pflanzenmargarine.The highest content of linoleic acid is found in vegetable oils such as safflower or safflower oil, sunflower hemp and soybean oil, and vegetable margarine.
Die dreifach ungesättigte alpha-Linolensäure (9,12,15-Octadecatriensäure) ist vor allem in Leinöl (55%), Walnußöl (14%), Rapsöl (11 %) und Hanföl (7%) enthalten.The threefold unsaturated alpha-linolenic acid (9,12,15-octadecatrienoic acid) is mainly present in linseed oil (55%), walnut oil (14%), rapeseed oil (11%) and hemp oil (7%).
Die folgende Tabelle 1 zeigt wichtige Omega-3- und -6-Fettsäuren, deren Kettenlänge und Lage der Doppelbindung sowie deren Vorkommen.The following Table 1 shows important omega-3 and 6-fatty acids, their chain length and position as well as their occurrence.
Tabelle 1 :Table 1 :
Quelle: Singer P., Was sind Omega-3-Fettsäuren, Frankfurt 1994
Vorzugsweise werden für die erfindungsgemäßen Formulierungen ungesättigte Fettsäuren aus der Gruppe ausgewählt, welche Ölsäure, Eicosapentaensäure, Timnodonsäure, Docosahexaensäure, Arachidonsäure, Linolsäure, α- Linolensäure, γ-l_inolensäure sowie Mischungen der vorgenannten Fettsäuren umfasst. Diese Mischungen umfassen insbesondere Mischungen der reinen ungesättigten Verbindungen. Erfindungsgemäß werden bevorzugt Öle als Komponente b eingesetzt, welche mindestens 20%, bevorzugt mindestens 25%, weiter bevorzugt mindestens 30% und insbesondere bevorzugt mindestens 35% an Omega-Fettsäuren enthalten. Unter den Omega-Fettsäuren sind insbesondere die Omega-9-Fettsäuren bevorzugt und unter den Omega-9-Fettsäuren insbesondere die Ölsäure. Ferner sind die Omega-6-Fettsäuren für die Herstellung der erfindungsgemäßen Formulierung besonders geeignet und unter den Omega-6-Fettsäuren die Linolsäure. Source: Singer P., What are omega-3 fatty acids, Frankfurt 1994 For the formulations according to the invention, unsaturated fatty acids are preferably selected from the group comprising oleic acid, eicosapentaenoic acid, timnodonic acid, docosahexaenoic acid, arachidonic acid, linoleic acid, α-linolenic acid, γ-1-nolinic acid and mixtures of the abovementioned fatty acids. These mixtures comprise in particular mixtures of the pure unsaturated compounds. According to the invention, oils are preferably used as component b which contain at least 20%, preferably at least 25%, more preferably at least 30% and especially preferably at least 35% of omega fatty acids. Among the omega fatty acids, especially the omega-9 fatty acids are preferred and among the omega-9 fatty acids in particular the oleic acid. Furthermore, the omega-6 fatty acids are particularly suitable for the production of the formulation according to the invention and the linoleic acid among the omega-6 fatty acids.
Die erfindungsgemäß als Komponente b eingesetzten Öle enthalten vorzugsweise mehr als 78 Gew.-% Öl- und Linolsäure, weiter bevorzugt mehr als 86 Gew.-% und insbesondere bevorzugt mehr als 93 Gew.-% Öl- und Linolsäure. Die als Komponente b verwendeten Öle enthalten bevorzugt mehr als 13 Gew.-% Ölsäure, weiter bevorzugt mehr als 24 Gew.-% Ölsäure und insbesondere bevorzugt mehr als 34 Gew.-% Ölsäure. Weitere bevorzugte Öle als Komponente b enthalten mehr als 38 Gew.-% Linolsäure (α-Linolsäure + ß- Linolsäure), vorzugsweise mehr als 47 Gew.-% Linolsäure, weiter bevorzugt mehr als 57 Gew.-% Linolsäure und insbesondere bevorzugt mehr als 67 Gew.-% Linolsäure. Ein weiteres insbesondere geeignetes Öl ist ein Sonnenblumenöl (Helianthus annuus L.) enthaltend 39 Gew.-% Ölsäure, 34 Gew.-% α-Linolsäure und 13 Gew.-% ß-Linolsäure,The oils used as component b according to the invention preferably contain more than 78% by weight of oleic and linoleic acid, more preferably more than 86% by weight and more preferably more than 93% by weight of oleic and linoleic acid. The oils used as component b preferably contain more than 13% by weight of oleic acid, more preferably more than 24% by weight of oleic acid and more preferably more than 34% by weight of oleic acid. Further preferred oils as component b contain more than 38% by weight of linoleic acid (α-linoleic acid + β-linoleic acid), preferably more than 47% by weight of linoleic acid, more preferably more than 57% by weight of linoleic acid and particularly preferably more than 67% by weight of linoleic acid. Another particularly suitable oil is a sunflower oil (Helianthus annuus L.) containing 39% by weight of oleic acid, 34% by weight of α-linoleic acid and 13% by weight of β-linoleic acid,
Als Öle werden bevorzugt Leinöl, Hanföl, Maiskeimöl, Walnussöl, Rapsöl, Sojaöl, Sonnenblumenöl, Mohnöl, Safloröl (Färberdistelöl), Weizenkeimöl, Distelöl, Traubenkemöl, Nachtkerzenöl, Borretschöl, Schwarzkümmelöl, Algenöl, Fischöl, Lebertran und/oder Mischungen der vorgenannten Öle eingesetzt. Insbesondere geeignet ist Sonnenblumenöl. Ferner ist möglich, den Ölen einzelne oder mehrere essentielle Fettsäuren beizumischen, um die notwendige Menge an essentiellen Fettsäuren bereitzustellen. Fischöl und Lebertran enthalten hauptsächlich Eicosapentaensäure (EPA C20:5) und Docosahexaensäure (DHA C22:6) neben wenig alpha-Linolensäure (ALA C18:3). Omega-3-Fettsäuren finden sich nicht nur in Fischöl, sondern auch in Pflanzenölen.
Die folgende Tabelle 2 zeigt eine Aufstellung der Fettsäurebestandteile in verschiedenen Ölen.Preferred oils are linseed oil, hemp oil, corn oil, walnut oil, rapeseed oil, soybean oil, sunflower oil, poppy seed oil, safflower oil, wheat germ oil, thistle oil, grape seed oil, evening primrose oil, borage oil, black cumin oil, algae oil, fish oil, cod liver oil and / or mixtures of the aforementioned oils , Particularly suitable is sunflower oil. It is also possible to add one or more essential fatty acids to the oils to provide the necessary amount of essential fatty acids. Fish oil and cod liver oil mainly contain eicosapentaenoic acid (EPA C20: 5) and docosahexaenoic acid (DHA C22: 6) in addition to low alpha-linolenic acid (ALA C18: 3). Omega-3 fatty acids are found not only in fish oil but also in vegetable oils. Table 2 below shows a list of fatty acid components in various oils.
Tabelle 2Table 2
Die folgenden Tabellen 3, 4 und 5 zeigen eine Auflistung von monoolefinischen, polyungesättigten sowie acetylenischen Fettsäuren, welche bei der vorliegenden Erfindung bevorzugt eingesetzt werden.The following Tables 3, 4 and 5 show a list of monoolefinic, polyunsaturated and acetylenic fatty acids which are preferably used in the present invention.
Tabelle 3: Monoolefinische FettsäurenTable 3: Monoolefinic fatty acids
Tabelle 4: Polyungesättigte Fettsäuren Table 4: Polyunsaturated fatty acids
Zusammen mit den essentiellen Fettsäuren können auch nicht essentielle Fettsäuren oder trans-Fettsäuren der erfindungsgemäßen Formulierung zugesetzt werden, wobei die oben genannte Gewichtsprozentangabe von mindestens 30 Gew.-%, bevorzugt 40 Gew.-% und insbesondere von mindestens 50 Gew.-% an essentiellen Fettsäuren nicht unterschritten werden sollte.
Die maximale Gewichtsmenge an essentiellen Fettsäuren sollte hingegen 25 g pro 100 g Formulierung nicht überschreitenNon-essential fatty acids or trans-fatty acids may also be added to the formulation according to the invention together with the essential fatty acids, the abovementioned weight percentage being at least 30% by weight, preferably 40% by weight and in particular at least 50% by weight of essential Fatty acids should not fall below. The maximum amount by weight of essential fatty acids, however, should not exceed 25 g per 100 g formulation
Tabelle 5: Acetylenische FettsäurenTable 5: Acetylenic fatty acids
Des weiteren enthalten die erfindungsgemäßen kosmetischen und/oder dermatologischen Formulierungen Glycerin als 85%ige Lösung in Wasser, Propylenglykol bzw. Polyethylenglykol als Konsistenzgeber, Benzyialkohol, Benzylaceton und/oder Benzaldehyd sowie Phenylethylalkohol und/oder 2- Phenylacetat. Das verwendete Glycerin kann einen Wassergehalt bis zu 20% aufweisen. Anstelle von Glycerin oder in Kombination mit Glycerin können Ethylenglykol, 1 ,3-Propandiol, tert-Butylalkoho! und/oder Alkohole mit Siedepunkten über 125°C bevorzugt über 15O0C und bevorzugt Diole oder Triole eingesetzt werden.Furthermore, the cosmetic and / or dermatological formulations according to the invention contain glycerol as an 85% solution in water, propylene glycol or polyethylene glycol as bodying agent, benzyl alcohol, benzylacetone and / or benzaldehyde and also phenylethyl alcohol and / or 2-phenylacetate. The glycerol used can have a water content of up to 20%. Instead of glycerol or in combination with glycerol, ethylene glycol, 1, 3-propanediol, tert-butyl alcohol! and / or alcohols having boiling points above 125 ° C preferably above 15O 0 C and preferably diols or triols are used.
Benzyialkohol, Benzylaceton und/oder Benzaldehyd werden als Permeabilitätsverbesserer zur Beschleunigung der Stoffwechselvorgänge in der Haut sowie als Stabilisierungsmittel für die Formulierung zugesetzt.Benzyl alcohol, benzylacetone and / or benzaldehyde are added as permeability enhancers to accelerate metabolic processes in the skin as well as stabilizing agents for the formulation.
Phenylethylalkohol und 2-Phenylacetat dienen ebenfalls als Permeabilitätsverbesserer für die Beschleunigung der Stoffwechselvorgänge in der Haut und stabilisieren zudem die Formulierung.Phenylethyl alcohol and 2-phenylacetate also serve as permeability enhancers for accelerating metabolic processes in the skin and also stabilize the formulation.
Insbesondere Benzyialkohol sowie Phenylethylalkohol führen zudem zu einem unerwarteten synergistischen Effekt zwischen den Komponenten der erfindungsgemäßen kosmetischen und/oder dermatologischen Formulierung, was
zur Folge hat, dass bei sehr guter Feuchtigkeitsversorgung der Haut, die Stoffwechselvorgänge in der Haut angeregt und beschleunigt werden und zudem eine Unterstützung der Lipidbarriere stattfindet. Dadurch sind die erfindungsgemäßen Formulierungen sowohl für die Behandlung von geschädigter Haut geeignet als auch für die Glättung von Falten bei längerer Anwendung. Somit werden Formulierungen bereitgestellt, welche nicht nur für die dermatologische Anwendung beispielsweise bei Akne, Neurodermitis und/oder Dermatitis geeignet sind, sondern gleichzeitig auch einen kosmetischen Effekt erzielen, beispielsweise die Glättung von Falten durch die Unterstützung des Aufbaus als auch der Regeneration der Lipidbarriere und/oder der Anregung als auch Beschleunigung der Stoffwechselvorgänge in der Haut. Insbesondere vorteilhaft ist die Zugabe von Benzylalkohol und/oder Phenylethylalkohol, welche neben einem ausgeprägten synergistischen Effekt auch zu einer deutlichen Viskositätserhöhung beitragen. Diese insbesondere durch Benzylalkohol erreichte signifikante spontane Viskositätserhöhung ist für die Matrix- oder Gelgerüstbildung und somit für die dermatologische/kosmetische Funktion der erfindungsgemäßen Formulierungen wesentlich. Diese beiden Komponenten und insbesondere der Benzylalkohol scheinen eine wichtige Rolle bei der Gerüstbildung in der Formulierung zu spielen. Durch Zusatz dieser Komponenten wird die Feuchtigkeitsversorgung der Haut deutlich gesteigert. Eine weitere wichtige Komponente der Formulierung ist Propylenglykol, welche bevorzugt in Gewichtsprozentmengen von mindestens 8 Gew.-%, weiter bevorzugt 9 Gew.-%, 10 Gew.-%, 11 Gew.-%, 12 Gew.-%, 13 Gew.-%, und insbesondere bevorzugt 14 Gew.-% eingesetzt wird. Die Funktion von Propylenglykol bei der Ausbildung der besonderen Gerüststruktur der erfindungsgemäßen Formulierungen ist noch nicht geklärt, ein Effekt auf die Konsistenz der Formulierung jedoch eindeutig nachweisbar.In particular, benzylic alcohol and phenylethyl alcohol also lead to an unexpected synergistic effect between the components of the cosmetic and / or dermatological formulation according to the invention, which As a result, with very good moisturizing of the skin, metabolic processes in the skin are stimulated and accelerated and, in addition, a support of the lipid barrier takes place. As a result, the formulations according to the invention are suitable both for the treatment of damaged skin and for the smoothing of wrinkles with prolonged use. Thus, formulations are provided which are not only suitable for dermatological use, for example in acne, atopic dermatitis and / or dermatitis, but at the same time also achieve a cosmetic effect, for example the smoothing of wrinkles by the support of the structure as well as the regeneration of the lipid barrier and / or the stimulation as well as acceleration of metabolic processes in the skin. Particularly advantageous is the addition of benzyl alcohol and / or phenylethyl alcohol, which also contribute to a marked increase in viscosity in addition to a pronounced synergistic effect. This significant spontaneous increase in viscosity achieved in particular by benzyl alcohol is essential for the matrix or gel skeleton formation and thus for the dermatological / cosmetic function of the formulations according to the invention. These two components, and in particular the benzyl alcohol, appear to play an important role in scaffolding in the formulation. By adding these components, the moisture supply to the skin is significantly increased. Another important component of the formulation is propylene glycol, which is preferably present in weight percentages of at least 8 wt%, more preferably 9 wt%, 10 wt%, 11 wt%, 12 wt%, 13 wt%. -%, And particularly preferably 14 wt .-% is used. The function of propylene glycol in the formation of the special framework structure of the formulations according to the invention has not yet been clarified, but an effect on the consistency of the formulation is clearly detectable.
Die erfindungsgemäßen kosmetischen und/oder dermatologischen Formulierungen enthalten Lecithin in einer Menge von 0,5 - 20,0 Gew.-%, bevorzugt 2,0 - 10,0 Gew.-%, ferner bevorzugt 3,0 - 5,0 Gew.-% und insbesondere bevorzugt 4,0 Gew.-%.The cosmetic and / or dermatological formulations according to the invention contain lecithin in an amount of 0.5-20.0% by weight, preferably 2.0-10.0% by weight, more preferably 3.0-5.0% by weight. -%, and more preferably 4.0 wt .-%.
Glycerin wird als eine 85%-Lösung in Wasser in einer Menge von 0,5 - 30,0 Gew.-%, bevorzugt 3,0 - 10,0 Gew.-%, femer bevorzugt 5,0 - 7,0 Gew.-%, noch weiter bevorzugt 4,5 - 6,0 Gew.-% und insbesondere bevorzugt 5,0 Gew.-% eingesetzt. Ethylenglykol, 1 ,3-Propandiol, tert-Butylalkohol, oder andere Diole oder Triole oder Alkohole mit Siedepunkten über 125°C bzw. 1500C werden
anstelle von Glycerin oder zusammen mit Glycerin in Mengen zugesetzt, so dass die vorgenannten Bereiche nicht über- oder unterschritten werden.Glycerol is added as an 85% solution in water in an amount of 0.5-30.0% by weight, preferably 3.0-10.0% by weight, more preferably 5.0-7.0% by weight. -%, even more preferably 4.5 to 6.0 wt .-% and particularly preferably 5.0 wt .-% used. Ethylene glycol, 1, 3-propanediol, tert-butyl alcohol, or other diols or triols or alcohols having boiling points above 125 ° C or 150 0 C. instead of glycerol or added together with glycerol in amounts such that the aforementioned ranges are not exceeded or fallen below.
Die Menge an verwendetem Propylenglykol und/oder Polyethylenglykol beträgt 0,5 - 50,0 Gew.-%, bevorzugt 6 - 35 Gew.-%, 7 - 30 Gew.-%, 7,5 - 28 Gew.-%, 8 - 26 Gew.-%, 8,5 - 25 Gew.-%, 9 - 24 Gew.-%, 9,5 - 23 Gew.-%, weiter bevorzugt 10,0 - 22,0 Gew.-%, ferner bevorzugt 11 - 21 Gew.-%, 12 - 20 Gew.-%, 13 - 19 Gew.-%, noch weiter bevorzugt 14,0 - 18,0 Gew.-%, femer noch weiter bevorzugt 15 - 17 Gew.-% und insbesondere bevorzugt 16,0 Gew.-%. Zudem ist bevorzugt, wenn die vorgenannten Gewichtsprozentangaben nur für Propylenglykol stehen, d.h. Polyethylenglykol nicht vorhanden ist. Vorteilhaft sind daher nur geringe Mengen an Polyethylenglykol bis maximal 30% des Gewichtsprozentanteils von Propylenglykol, vorzugsweise bis maximal 20%, weiter bevorzugt bis maximal 20%, noch weiter bevorzugt bis maximal 15% und insbesondere bevorzugt bis maximal 10% des Gewichtsprozentanteiis von Propylenglykol.The amount of propylene glycol and / or polyethylene glycol used is 0.5-50.0 wt%, preferably 6-35 wt%, 7-30 wt%, 7.5-28 wt%, 8 - 26 wt .-%, 8.5 - 25 wt .-%, 9 - 24 wt .-%, 9.5 - 23 wt .-%, more preferably 10.0 - 22.0 wt .-%, further preferably 11-21% by weight, 12-20% by weight, 13-19% by weight, even more preferably 14.0-18.0% by weight, furthermore preferably 15-17% by weight. % and most preferably 16.0 wt .-%. In addition, it is preferred if the aforementioned weight percentages are only for propylene glycol, i. Polyethylene glycol is not present. Advantageously, therefore, only small amounts of polyethylene glycol to a maximum of 30% by weight of propylene glycol, preferably up to 20%, more preferably up to 20%, even more preferably up to 15% and most preferably up to 10% of the Gewichtsprozentanteiis of propylene glycol.
Benzylalkohol, Benzylaceton und/oder Benzaldehyd werden in einer Menge von 0,1 - 15,0 Gew.-%, bevorzugt 1 ,0 - 5,0 Gew.-%, ferner bevorzugt 2,0 - 4,0 Gew.- % und insbesondere bevorzugt von 3,0 Gew.-% eingesetzt.Benzyl alcohol, benzylacetone and / or benzaldehyde are used in an amount of 0.1-15.0% by weight, preferably 1.0-10.0% by weight, more preferably 2.0-4.0% by weight. and particularly preferably used of 3.0 wt .-%.
Die erfindungsgemäßen kosmetischen und/oder dermatologischen Formulierungen enthalten Phenylethylalkohol und/oder 2-Phenylacetat in einer Menge von 0,1 - 15,0 Gew.-%, bevorzugt 0,2 - 5,0 Gew.-%, ferner bevorzugt 0,3 - 1 ,5 Gew.-% und insbesondere bevorzugt 0,5 Gew.-%.The cosmetic and / or dermatological formulations according to the invention comprise phenylethyl alcohol and / or 2-phenylacetate in an amount of 0.1-15.0% by weight, preferably 0.2-5.0% by weight, furthermore preferably 0.3 - 1, 5 wt .-% and particularly preferably 0.5 wt .-%.
Den vorgenannten Bestandteilen wird gereinigtes Wasser in einer Menge zugesetzt, dass die Formulierung zu 100 Gew.-% (ad 100 Gew.-%) ergänzt wird.Purified water is added to the above ingredients in an amount to supplement the formulation to 100% by weight (ad 100% by weight).
Insbesondere bevorzugt ist eine Formulierung aus den folgenden Bestandteilen: Lecithin, natives Öl mit einem definierten Gehalt an essentiellen Fettsäuren wie z.B. Sonnenblumenöl sowie Glycerin, Propylenglykol, Benzylalkohol, Phenylethylalkohol und gereinigtes Wasser.Especially preferred is a formulation of the following ingredients: lecithin, native oil with a defined content of essential fatty acids, such as e.g. Sunflower oil and glycerin, propylene glycol, benzyl alcohol, phenylethyl alcohol and purified water.
Den erfindungsgemäßen Zusammensetzungen können ferner noch übliche Geruchsstoffe bzw. Parfüms, Farbstoffe, Konservierungsstoffe, Viskositätserhöhende Stoffe und/oder UV-Filter zugesetzt werden. Diese Zusätze dienen insbesondere zur Erhöhung der Färb-, Licht- und/oder Parfümstabilität der
Formulierungen bzw. der Haltbarkeit oder Konsistenzgebung. Derartige Zusatzstoffe sind insgesamt in nicht mehr als 10 Gew.-%, bevorzugt 8 Gew.-%, weiter bevorzugt 6 Gew.-% und insbesondere bevorzugt 4 Gew.-% in der Formulierung vorhanden.The compositions according to the invention may also be supplemented with customary odorants or perfumes, dyes, preservatives, viscosity-increasing substances and / or UV filters. These additives are used in particular to increase the color, light and / or perfume stability of Formulations or shelf life or consistency. Such additives are present in total in not more than 10 wt .-%, preferably 8 wt .-%, more preferably 6 wt .-% and particularly preferably 4 wt .-% in the formulation.
Die erfindungsgemäßen kosmetischen und/oder dermatologischen Formulierungen können vorteilhaft für die Behandlung aller Formen von unreiner bis hin zu geschädigter Haut eingesetzt werden. Unter unreiner bis hin zu geschädigter Haut sind beispielsweise alle Formen von Akne, Neurodermitis oder atypische Dermatitis zu verstehen.The cosmetic and / or dermatological formulations according to the invention can advantageously be used for the treatment of all forms from impure to damaged skin. From blemished to damaged skin, for example, all forms of acne, atopic dermatitis or atypical dermatitis are to be understood.
Unter kosmetischer und/oder dermatologischer Formulierungen sind insbesondere Hautcremes, Hautlotionen, Milche, Salben, Öle sowie Balsame und sämtliche andere zur topischen Anwendung geeignete Formulierungen zu verstehen.Cosmetic and / or dermatological formulations are, in particular, skin creams, skin lotions, milks, ointments, oils and balms and all other formulations suitable for topical application.
Die folgenden Beispiele sollen die Erfindung verdeutlichen, ohne sie einzuschränken.
Beispiele Beispiel 1:
Beispiel 4:
Beispiel 7:
Beispiel 10:The following examples are intended to illustrate the invention without limiting it. Examples Example 1: Example 4: Example 7: Example 10:
Nachweis der Viskositätserhöhung: Eine Suspension aus 100 g Lecithin (Phosphatidylcholin 8OH, Fa. Lipoid) und 900 g Wasser wird mit 20 g Benzylalkohol bei 30 - 4O0C vermischt. Die Viskosität vor der Zugabe des Benzylalkohols betrug ca. 2180 mPas (Haake RV/7 (Brookfield) Tauchkörper R3, 30 up/m, 38°C) nach der Zugabe des Benzylalkohols jedoch ca. 54790 mPas (Tauchkörper R5, 4 up/m, 34°C).Detection of the viscosity increase: A suspension of 100 g of lecithin (phosphatidylcholine 8OH, Fa. Lipoid) and 900 g of water is mixed with 20 g of benzyl alcohol at 30 - 4O 0 C. The viscosity before the addition of the benzyl alcohol was about 2180 mPas (Haake RV / 7 (Brookfield) immersion R3, 30 up / m, 38 ° C) after the addition of benzyl alcohol but about 54790 mPas (immersion R5, 4 up / m , 34 ° C).
Die Wertablesung erfolgte nach je 2 Minuten.The value was read every 2 minutes.
Die Viskositätserhöhung ist von Dauer.
The viscosity increase is permanent.
Claims
1. Kosmetische und/oder dermatologische Formulierung enthaltend folgende Bestandteile: a) Lecithin, b) Öl mit hohem Gehalt an essentiellen Fettsäuren, c) Glycerin, Ethylenglykol, 1 ,3-Propandiol und/oder tert-Butylalkohol, d) Propylenglykol und/oder Polyethylenglykol, e) Benzylalkohol und/oder Phenylethylalkohol, f) gereinigtes Wasser.1. Cosmetic and / or dermatological formulation comprising the following ingredients: a) lecithin, b) oil with high content of essential fatty acids, c) glycerol, ethylene glycol, 1, 3-propanediol and / or tert-butyl alcohol, d) propylene glycol and / or Polyethylene glycol, e) benzyl alcohol and / or phenylethyl alcohol, f) purified water.
2. Kosmetische und/oder dermatologische Formulierung nach Anspruch 1 enthaltend folgende Bestandteile: a) Lecithin, b) Öl mit hohem Gehalt an essentiellen Fettsäuren, c) Glycerin, d) Propylenglykol, e) Benzylalkohol und/oder Phenylethylalkohol, f) gereinigtes Wasser.2. Cosmetic and / or dermatological formulation according to claim 1 containing the following ingredients: a) lecithin, b) oil with high content of essential fatty acids, c) glycerol, d) propylene glycol, e) benzyl alcohol and / or phenylethyl alcohol, f) purified water.
3. Kosmetische und/oder dermatologische Formulierung nach Anspruch 1 oder 2, des weiteren enthaltend die Bestandteile g) Benzylaceton und/oder Benzaldehyd, h) 2-Phenylacetat.3. Cosmetic and / or dermatological formulation according to claim 1 or 2, further comprising the ingredients g) benzylacetone and / or benzaldehyde, h) 2-phenylacetate.
4. Kosmetische und/oder dermatologische Formulierung gemäß einem der vorherigen Ansprüche, worin das Lecithin aus Hühnerei und/oder Soja gewonnen wird.4. Cosmetic and / or dermatological formulation according to one of the preceding claims, wherein the lecithin from chicken egg and / or soybean is obtained.
5. Kosmetische und/oder dermatologische Formulierung gemäß einem der vorherigen Ansprüche, worin das Öl nativen Ursprungs einen Gehalt an essentiellen Fettsäuren von mindestens 30 Gew.-%, bevorzugt 40 Gew.-% und insbesondere bevorzugt von mindestens 50 Gew.-% aufweist.Cosmetic and / or dermatological formulation according to one of the preceding claims, wherein the oil of native origin has an essential fatty acid content of at least 30% by weight, preferably 40% by weight and more preferably of at least 50% by weight.
6. Kosmetische und/oder dermatologische Formulierung gemäß einem der vorherigen Ansprüche, worin es sich bei den essentiellen Fettsäuren um Omega-Fettsäuren, bevorzugt Ölsäure und Linolsäure handelt. Cosmetic and / or dermatological formulation according to any one of the preceding claims, wherein the essential fatty acids are omega fatty acids, preferably oleic acid and linoleic acid.
7. Kosmetische und/oder dermatologische Formulierung gemäß einem der vorherigen Ansprüche, worin Lecithin in einer Menge von 0,5 - 20,0 Gew.-%, bevorzugt 2,0 - 10,0 Gew.-%, ferner bevorzugt 3,0 - 5,0 Gew.-% und insbesondere 4,0 Gew.-% enthalten ist.Cosmetic and / or dermatological formulation according to one of the preceding claims, wherein lecithin is present in an amount of 0.5-20.0% by weight, preferably 2.0-10.0% by weight, further preferably 3.0 - 5.0 wt .-% and in particular 4.0 wt .-% is contained.
8. Kosmetische und/oder dermatologische Formulierung gemäß einem der vorherigen Ansprüche, worin das Öl nativen Ursprungs in einer Menge von 3,0 - 20,0 Gew.-%, bevorzugt 6,0 - 16,0 Gew.-%, femer bevorzugt 8,0 - 12,0 Gew.-% und insbesondere 10,0 Gew.-% enthalten ist.Cosmetic and / or dermatological formulation according to one of the preceding claims, wherein the oil of native origin is present in an amount of 3.0-20.0% by weight, preferably 6.0-16.0% by weight, moreover preferred 8.0 to 12.0 wt .-% and in particular 10.0 wt .-% is included.
9. Kosmetische und/oder dermatologische Formulierung gemäß einem der vorherigen Ansprüche, worin Glycerin als 85%ige-Lösung, Et-hylenglykol, 1 ,3- Propandiol und/oder tert-Butylalkohol in einer Menge von 0,5 - 30,0 Gew.-%, bevorzugt 3,0 - 10,0 Gew.-%, ferner bevorzugt 5,0 - 7,0 Gew.-% und insbesondere 5,0 Gew.-% enthalten ist/sind.9. Cosmetic and / or dermatological formulation according to one of the preceding claims, wherein glycerol as 85% solution, Et-hylenglykol, 1, 3-propanediol and / or tert-butyl alcohol in an amount of 0.5 - 30.0 wt %, preferably 3.0-10.0% by weight, further preferably 5.0-7.0% by weight and in particular 5.0% by weight is / are contained.
10. Kosmetische und/oder dermatologische Formulierung gemäß einem der vorherigen Ansprüche, worin Propylenglykol und/oder Polyethylenglykol in einer Menge von 0,5 - 50,0 Gew.-%, bevorzugt 10,0 - 22,0 Gew.-%, ferner bevorzugt 14,0 - 18,0 Gew.-% und insbesondere 16,0 Gew.-% enthalten ist/sind.10. Cosmetic and / or dermatological formulation according to one of the preceding claims, wherein propylene glycol and / or polyethylene glycol in an amount of 0.5 to 50.0 wt .-%, preferably 10.0 to 22.0 wt .-%, further preferably 14.0 - 18.0 wt .-% and in particular 16.0 wt .-% is / are included.
11. Kosmetische und/oder dermatologische Formulierung gemäß einem der vorherigen Ansprüche, worin Benzylalkohol, Benzylaceton und/oder Benzaldehyd in einer Menge von 0,1 - 15,0 Gew.-%, bevorzugt 1 ,0 - 5,0 Gew.-%, ferner bevorzugt 2,0 - 4,0 Gew.-% und insbesondere 3,0 Gew.-% enthalten ist/sind.11. Cosmetic and / or dermatological formulation according to one of the preceding claims, in which benzyl alcohol, benzylacetone and / or benzaldehyde in an amount of 0.1-15.0% by weight, preferably 1, 0-5.0% by weight , further preferably 2.0 to 4.0 wt .-% and in particular 3.0 wt .-% is / are included.
12. Kosmetische und/oder dermatologische Formulierung gemäß einem der vorherigen Ansprüche, worin Phenylethylalkohol und/oder 2-Phenylacetat in einer Menge von 0,1 - 15,0 Gew.-%, bevorzugt 0,2 - 5,0 Gew.-%, ferner bevorzugt 0,3 - 1 ,5 Gew.-% und insbesondere 0,5 Gew.-% enthalten ist/sind.12. Cosmetic and / or dermatological formulation according to one of the preceding claims, wherein phenylethyl alcohol and / or 2-phenyl acetate in an amount of 0.1 to 15.0 wt .-%, preferably 0.2 to 5.0 wt .-% , Further preferably 0.3 to 1, 5 wt .-% and in particular 0.5 wt .-% is / are included.
13. Verwendung der kosmetischen und/oder dermatologischen Formulierung gemäß eines der Patentansprüche 1 - 10 zur Erzeugung eines angenehmen Hautgefühls gemäß Hautrauhigkeitstest. 13. Use of the cosmetic and / or dermatological formulation according to one of the claims 1-10 for the generation of a pleasant skin feel according to skin roughness test.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004031210A DE102004031210A1 (en) | 2004-06-28 | 2004-06-28 | MLV cosmetic |
PCT/DE2005/001112 WO2006000196A1 (en) | 2004-06-28 | 2005-06-22 | Mlv cosmetic product |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1763335A1 true EP1763335A1 (en) | 2007-03-21 |
Family
ID=34972329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05759725A Withdrawn EP1763335A1 (en) | 2004-06-28 | 2005-06-22 | Mlv cosmetic product |
Country Status (12)
Country | Link |
---|---|
US (1) | US20060257352A1 (en) |
EP (1) | EP1763335A1 (en) |
JP (1) | JP2007500732A (en) |
CN (1) | CN1838939A (en) |
AU (1) | AU2005256090A1 (en) |
BR (1) | BRPI0505988A (en) |
CA (1) | CA2567288A1 (en) |
DE (2) | DE102004031210A1 (en) |
IL (1) | IL173511A0 (en) |
RU (1) | RU2323713C2 (en) |
WO (1) | WO2006000196A1 (en) |
ZA (1) | ZA200600423B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5403569B2 (en) * | 2006-05-24 | 2014-01-29 | 有限会社大長企画 | Strength enhancer |
GB0625069D0 (en) | 2006-12-15 | 2007-01-24 | Givaudan Sa | Compositions |
FR2940281B1 (en) * | 2008-12-22 | 2011-04-01 | Fabre Pierre Dermo Cosmetique | ESTER OF DIOL AND POLYUNSATURATED FATTY ACID AS ANTI-ACNE AGENT |
US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
US8673325B1 (en) * | 2012-09-06 | 2014-03-18 | Dignity Sciences Limited | Cosmetic compositions comprising EPA and salicylic acid and methods of making and using same |
US8986755B1 (en) * | 2013-12-05 | 2015-03-24 | Sherry May Raymond-Coblantz | Skin moisturizer |
US8986752B1 (en) * | 2013-12-05 | 2015-03-24 | Sherry May Raymond-Coblantz | Skin care treatment |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL281225A (en) * | 1961-07-20 | |||
DE4021083C2 (en) * | 1990-07-03 | 1995-08-17 | Hans Dr Lautenschlaeger | Phospholipid formulations and their use for the preparation of liposomal medical and cosmetic baths |
US5922331A (en) * | 1997-03-26 | 1999-07-13 | Chanel, Inc. | Skin cream composition |
DE19857491A1 (en) * | 1998-12-14 | 2000-06-15 | Hans Lautenschlaeger | Cosmetic or dermatological skin-protective compositions, containing UV filter and saturated phosphatidyl choline to give good barrier stabilizing and active agent penetrating effects |
DE10108097A1 (en) * | 2000-02-25 | 2001-09-13 | Kuhs Kosmetik Gmbh & Co Kg | Cosmetic formulation, especially for use on aging and/or stressed skin, contains trimethylammonium-methyl compound, metabolite and/or S-adenosylmethionine besides water and substance forming lamellar structures with water |
EP1138313A1 (en) * | 2000-03-28 | 2001-10-04 | Primacare S.A. | Proliposomes |
EP1138310A1 (en) * | 2000-03-28 | 2001-10-04 | Primacare S.A. | Proliposomes |
FR2832630B1 (en) * | 2001-11-28 | 2005-01-14 | Oreal | COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING AT LEAST ONE OXIDATION-SENSITIVE HYDROPHILIC ACTIVE STABILIZED WITH AT LEAST ONE COPOLYMER OF N-VINYLIMIDAZOLE |
-
2004
- 2004-06-28 DE DE102004031210A patent/DE102004031210A1/en not_active Withdrawn
-
2005
- 2005-06-22 WO PCT/DE2005/001112 patent/WO2006000196A1/en active Application Filing
- 2005-06-22 US US10/569,770 patent/US20060257352A1/en not_active Abandoned
- 2005-06-22 JP JP2006523524A patent/JP2007500732A/en active Pending
- 2005-06-22 EP EP05759725A patent/EP1763335A1/en not_active Withdrawn
- 2005-06-22 DE DE112005002139T patent/DE112005002139A5/en not_active Withdrawn
- 2005-06-22 RU RU2006105335/15A patent/RU2323713C2/en not_active IP Right Cessation
- 2005-06-22 BR BRPI0505988-7A patent/BRPI0505988A/en not_active IP Right Cessation
- 2005-06-22 CA CA002567288A patent/CA2567288A1/en not_active Abandoned
- 2005-06-22 AU AU2005256090A patent/AU2005256090A1/en not_active Abandoned
- 2005-06-22 CN CNA2005800007546A patent/CN1838939A/en active Pending
- 2005-06-22 ZA ZA200600423A patent/ZA200600423B/en unknown
-
2006
- 2006-02-02 IL IL173511A patent/IL173511A0/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO2006000196A1 * |
Also Published As
Publication number | Publication date |
---|---|
RU2323713C2 (en) | 2008-05-10 |
AU2005256090A8 (en) | 2008-09-25 |
DE112005002139A5 (en) | 2007-09-06 |
ZA200600423B (en) | 2007-04-25 |
AU2005256090A1 (en) | 2006-02-16 |
CN1838939A (en) | 2006-09-27 |
JP2007500732A (en) | 2007-01-18 |
RU2006105335A (en) | 2007-09-10 |
BRPI0505988A (en) | 2006-10-24 |
US20060257352A1 (en) | 2006-11-16 |
CA2567288A1 (en) | 2006-01-05 |
IL173511A0 (en) | 2006-07-05 |
WO2006000196A1 (en) | 2006-01-05 |
DE102004031210A1 (en) | 2006-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0607231B1 (en) | Use of an emulsion to prepare an intravenously administered medicament for treating skin diseases | |
DE69325896T2 (en) | Lipid composition for cosmetics containing unsaturated fatty acid triglycerides | |
DE69213930T2 (en) | FAT PREPARATIONS AND THEIR USE IN EMULSION PRODUCTS LIKE COSMETICS AND PHARMACEUTICALS | |
WO2006000196A1 (en) | Mlv cosmetic product | |
DE1910062B2 (en) | Vegetable margarine fat | |
WO2001062222A2 (en) | Cosmetic composition, especially for use on aging and/or stressed skin | |
DE602004004880T2 (en) | SKIN CARE PRODUCT WITH TALL OIL FATTY ACIDS AND PLANT OILS FOR DRY AND DANDRATING SKIN AND TREATMENT OF PSORIASIS, DERMATITIS AND ECCEMENTS | |
DE2514873A1 (en) | Hydrocarbon mixture ointment base - contg. water/oil emulsifiers and oil/water emulsifiers | |
DE102007031697A1 (en) | Cosmetic or pharmaceutical preparation | |
DE2832636A1 (en) | Fat compsn. contg. medium chain tri:glyceride mixt. - and hard fat, useful as basis for margarine | |
DE69010680T2 (en) | Skin bleaching cosmetics. | |
DE69904567T2 (en) | LIPID MIXTURE AND THEIR USE | |
EP0596953A1 (en) | Emulsifier concentrates | |
EP1503729B1 (en) | Composition and the use thereof as a pharmaceutical or cosmetic formulation for external use | |
EP0103854B1 (en) | Combinations of emulsifying agents for water-in-oil-type emulsions and their use | |
EP0972451A1 (en) | Oil-containing feed composition | |
DE69000689T2 (en) | FAT AND METHOD FOR THE PRODUCTION THEREOF. | |
EP1534234B1 (en) | Composition and use thereof as a pharmaceutical or cosmetic formulation for external application | |
MXPA06002343A (en) | Mlv cosmetic product | |
WO2024115575A1 (en) | Cosmetic composition containing an alcohol, a plant oil, a fatty acid monoester, an emulsifier and a plant ingredient | |
EP2929871B1 (en) | Cream for denture adhesive | |
DE102020127305A1 (en) | Cosmetic composition for lip augmentation | |
WO1995035088A1 (en) | Cosmetic and/or pharmaceutical o/w emulsions | |
DE102018222066A1 (en) | Process for the preparation of cosmetic emulsions comprising cold-pressed oils | |
AT281569B (en) | PROCESS FOR THE SEPARATION OF VEGETABLE PHOSPHATIDE FRACTIONS FROM A MIXTURE CONTAINING THIS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060105 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
17Q | First examination report despatched |
Effective date: 20070427 |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090225 |